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Abstract
Objectives: To assess the effect of non-squamous variant histology on survival in muscle 
invasive urothelial bladder cancer. 
Materials and Methods: A cohort of 411 radical cystectomy cases performed with curative intent 
for muscle invasive primary urothelial carcinoma (UC) was identified between 2008 and June 
2013.  Survival analysis was evaluated using Kaplan-Meier methodology comparing NV+SQD 
histology to non-SQD variant histology (non-SQD variants).  Multivariable cox proportional 
hazards regression assessed all-cause and disease specific mortality. 
Results: Of the 411 cystectomy cases, 77 (19%) were non-SQD variant histology. Median OS 
for non-SQD variant histology was 28 months, whereas the NV+SQD group had not reached 
median OS at 74 months (log rank test p<0.001). After adjusting for sex, age, pathologic stage, 
and any systemic chemotherapy, patients with non-SQD variant histology on cystectomy had a 
1.57 times increased adjusted risk of all-cause mortality (p=0.027) and 1.69 times increased risk 
of disease specific mortality (p=0.030) compared with NV+SQD patients. 
Conclusions: While SQD behaves similarly to NV, non-SQD variant histology portends worse 
OS and DSS regardless of neoadjuvant or adjuvant chemotherapy and pathologic stage.  Non-
SQD variants of UC could perhaps be considered a distinct clinical entity in UC with goals for 
developing new treatment algorithms through novel clinical trials. 
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Introduction 
Variant histology urothelial bladder cancer has been postulated to be part of a de-
differentiation pathway of aggressive disease and is recognized to present at a more advanced 
clinical stage. Nonetheless, it has not been regarded as predicting a worse outcome when 
adjusting for clinical and pathologic stage. Throughout the past decade, recognition of variant 
histology in urothelial bladder cancer (UC) has increased; however, definitive treatment 
algorithms for specific variants, aside from small cell, which is considered non-primary UC and 
managed similarly to small cell cancer of the lung [1], remain non-existent.  Part of the difficulty 
in determining best practices for variant histology UC relates to the small numbers of cases 
identified and poor sensitivity to identification by transurethral resection.[2]  Additionally, 
conflicting findings have been presented in the literature because of differences in study design 
and pre-operative clinical characteristics. This has limited decisive management and prognostic 
conclusions, even in well described examples such as micropapillary variant.[3-7]  Despite 
squamous differentiation (SQD) variant being clinically distinct from non-variant (NV) UC based 
on histopathologic and morphologic characteristics, there is evidence suggesting that SQD 
behaves similarly to NV when examining long term oncologic outcomes and response to 
chemotherapy.[3, 7-10] 
Considering the proposed equivalence of SQD and NV and the lack of definitive 
outcomes published on variant histology in UC [11], we sought to determine prognostic 
differences based on variant histology status in a contemporary cystectomy series when 
considering SQD and NV alike. In light of the recognition of variant histology in the 2004 bladder 
cancer WHO guidelines[1] and the increase in diagnosis of variant histology at our institution 
since then, we hypothesized that this contemporary series would allow higher incidence rates of 
variant histology to provide more accurate prognostic differences between the two groups. 
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Methods 
Patients and data source 
After obtaining Institutional Review Board approval of the study, a retrospective cohort 
analysis was performed using our institutional database.  All patients undergoing radical 
cystectomy between 2008 and June 2013 with UC on transurethral resection of bladder tumor 
(TURBT) and final cystectomy pathology were identified (n=698).  Only patients treated with 
curative intent were included.  As such, patients with metastatic disease, lymphadenopathy 
greater than 1.5 cm on pre-operative images, or undergoing bladder preservation protocols 
were excluded (n=52).  Additionally, patients with any component of small cell variant were 
excluded (n=22), given the recognition and management of small cell as a non-primary UC.[1] 
Finally, we eliminated all patients with clinically non-muscle invasive bladder cancer (n=213). 
Primary urothelial variant histology was assigned and confirmed by central pathologic review 
utilizing dedicated genito-urinary pathologists at our institution for cystectomy and transurethral 
resection (TUR) specimens (led by LC). In cases of TUR specimens from outside institutions, 
re-review of TUR pathology was performed prior to cystectomy with reassignment of variant 
histology if necessary. Histologic classification used in the analysis was based on cystectomy 
pathology: non-variant and squamous differentiation (NV+SQD) compared to all other non-
squamous differentiation variants (non-SQD). Non-SQD variant histology included 
micropapillary, plasmacytoid, sarcomatoid, glandular differentiation, nested, lymphoepithelioma-
like, giant cell, rhabdoid, and microcystic variants.   In the setting of mixed variant histology, the 
predominant variant (SQD or non-SQD variant) listed in the pathologic evaluation was used for 
the analysis. There was no percentage threshold used for variant histology.  Our reasoning for 
this was based on the assumption that any component of variant histology would drive any 
observed disparate outcomes.  
6 
This article is protected by copyright. All rights reserved. 
Variables and outcomes 
Clinical and pathologic characteristics evaluated were sex, age, race (Caucasian vs. 
non-Caucasian), clinical stage, neoadjuvant and adjuvant chemotherapy, pathologic stage, 
cystectomy histology, surgical margin status, lymph node status (LN+), non-organ confined 
disease, disease specific and overall survival.  Non-organ confined disease was defined as pT3, 
pT4, LN+, or positive surgical margins.  Survival data were obtained through our departmental 
database and institutional cancer registry. 
Statistical analysis 
Assessment of differences between NV+SQD and non-SQD groups was performed using 
Pearson’s chi-squared tests for categorical variables and Student’s t-test for continuous, 
normally distributed variables.  Kaplan Meier methodology and log-rank tests for equality of 
survivor functions were performed to assess for differences in survival.  Time zero was defined 
as the time of cystectomy. Cox proportional hazards regression was used to evaluate 
characteristics associated with all-cause and disease specific mortality, with the primary variable 
of interest being non-SQD variant histology at cystectomy.  We adjusted for age, sex, history of 
systemic chemotherapy for UC (neoadjuvant or adjuvant), and non-organ confined disease 
((pT3, pT4, LN+, or positive surgical margin).  Covariates included in the model were 
determined a priori based on clinical judgment of being a confounder.  We chose to group 
neoadjuvant and adjuvant chemotherapy into a single variable, as both forms of systemic 
chemotherapy have been shown to improve survival.[10, 12-14]  The proportional hazards 
assumption was tested using Schoenfield and scaled Schoenfield residuals, and all variables 
used in the final model satisfied the assumption. A priori, p-values <0.05 were considered 
statistically significant.  Microsoft Excel (Microsoft Inc.) and Stata version 12.1 (Stata Corp. LP, 
College Station, TX) were used for all statistical analyses.
7 
This article is protected by copyright. All rights reserved. 
Results 
Four hundred and eleven patients were identified with primary muscle invasive UC in the 
study period that underwent radical cystectomy with curative intent.   Of these, 278 (67.6%) 
were noted to have NV histology on cystectomy pathology, 56 (13.6%) had SQD, and 77 
(18.7%) had non-SQD variant histology.  Of the 77 non-SQD variant histology cases, only 32 
(42%) were identified as having variant histology on TURBT.  As shown in Table 1, patients 
were similar with respect to age, gender, race, and receipt of neoadjuvant chemotherapy 
between groups.  Nearly three times as many non-SQD patients underwent adjuvant 
chemotherapy (29% vs. 11%, p<0.001).  Overall, patients with non-SQD variant histology had a 
higher pathologic stage, incidence of positive lymph nodes, and incidence of positive surgical 
margins (Table 2). 
Among the 77 non-SQD variants, 22 were micropapillary variant (MPV), 17 plasmacytoid 
variant (PCV), 13 sarcomatoid variant (SAV), and 25 were comprised of variants occurring 
fewer than ten times in our cohort (eight glandular differentiation, six nested, five 
lymphoepithelioma-like, four clear-cell variant, and two rhabdoid variant).  Within the 19% of 
non-SQD patients who received neoadjuvant chemotherapy, this varied between 23% (n=5) of 
MPV, 29% (n=5) of PCV, 0 SAV, and 20% (n=5) of the other variants. The proportion of patients 
with non-organ confined disease was 68% (n=15) for MPV, 82% (n=14) for PCV, 62% (n=8) for 
SAV, and 68% (n=17) for the other variants which was significantly higher than among the 
NV+SQD patients (52%). 
Median follow-up was 38 months (range: 1-74), during which a total 150 patients died.  
115 (34%)  NV+SQD patients died compared 35 (45%) of non-SQD variant histology patients.  
Median overall survival time for each group is shown in Table 2.  Figures 1a and 1b shows the 
OS and DSS comparing NV+SQD with non-SQD variant (log-rank test p=0.007 each).  Two and 
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five year OS for the non-SQD variant histology patients was 58.1% and 45.0% compared with 
72.6% and 58.4% for NV+SQD. Two and five year DSS for non-SQD variant histology was 
66.9% and 44.8% versus 77.7% and 66.5% for NV+SQD. 
On multivariable cox proportional hazards regression, patients with non-SQD variant 
histology on cystectomy were at 1.57 times increased risk of all-cause mortality compared with 
NV+SQD patients, after controlling for pathologic stage, chemotherapy, and demographic 
characteristics (Table 3). Systemic chemotherapy was associated with a 40% decreased risk of 
all-cause mortality (p=0.012).  Non-SQD variant histology conferred 69% increased adjusted 
risk of disease specific mortality (Table 3). 
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Discussion 
Does variant histology in primary urothelial bladder cancer confer worse survival and 
should it be considered a separate disease entity with a different treatment algorithm from non-
variant histology? Herein, we have demonstrated that non-SQD variant histology portends 
worse overall and disease specific survival, independent of pathologic stage and reception of 
chemotherapy.   Previous literature has been inconclusive, which may be in part due to 
inclusion of patients with SQD in the variant histology group.  In a secondary analysis of the 
SWOG 8710 trial data, chemo-responsiveness and survival for SQD compared with NV UC 
were similar [10], and similar findings are demonstrated frequently in the published literature.[8, 
9, 15, 16] We suggest that rather than being included in the overall variant category, SQD 
should be considered similar to NV for the purpose of generating management algorithms and 
survival expectations. Neoadjuvant chemotherapy followed by consolidative cystectomy for 
locally advanced muscle invasive disease should remain the mainstay of treatment in SQD and 
NV patients. 
Recommendations for the management of non-SQD variant histology urothelial 
carcinoma vary, with some variants seemingly chemo-sensitive and others strikingly chemo-
resistant.  In the current study, we report that even after controlling for systemic chemotherapy, 
non-SQD variant histology was associated with worse mortality.  Although we did not 
specifically examine the effect of chemotherapy on individual non-SQD variants, findings from 
other institutions offer important insights into the role of chemotherapy in non-SQD variant 
histology.  For instance, recent institutional studies have suggested potential chemo-sensitivity 
for micropapillary variant.[4, 6]  This is a departure from prior studies which repeatedly showed 
that micropapillary variant is chemo-resistant with worse survival.[5, 17-19]  Similarly, 
plasmacytoid variant (PCV) is traditionally considered chemo-resistant with associated poor 
survival [20-23]; however, a recent study from Dayyani et al suggests that PCV might be initially 
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chemo-sensitive, although the high recurrence rate and poor OS in PCV patients limits the 
clinical relevance of this finding.[24]  Sarcomatoid variant is less commonly evaluated in the 
literature, particularly with regard to chemotherapeutic-responsiveness; however the current 
consensus is that it results in poor survival.[25,26] 
As recognition of variant histology improves in both community and academic settings, 
larger series will emerge that characterize less common variants such as nested and 
lymphoepithlioma-like variants. Multi-institutional collaborations will provide vital, prospective 
insights into variant histology management strategies.[27] However, even with large studies that 
are sufficiently powered to provide treatment recommendations, guidelines that include either 
neoadjuvant chemotherapy or early cystectomy will only be effective in addressing variant 
histology UC if it is found on TUR.  A recent article explored what proportion of variant histology 
identified on radical cystectomy was concurrently identified on TUR.2 Similar to our finding of 
42% of cystectomy non-SQD variant histology patients having variant histology identified on 
TURBT, Abd El-Latif et al noted that TUR was less than 40% sensitive for predicting cystectomy 
variant histology and that 67% of the PCV histology found on radical cystectomy was identified 
by immunohistochemical stains.[2]  These findings argue for investigation into the regular use of 
staining techniques and centralized pathologic review by dedicated genito-urinary pathologists 
for optimized detection of variant histology on TUR in order to maximize the effectiveness of any 
management algorithm. 
It is increasingly clear that traditional approaches to UC are not effective for non-SQD 
variant histology.  Perhaps now is the time to shift the direction of our long-term goals in 
advancing the care of UC patients through the development of novel treatment algorithms and 
personalized therapeutic approaches.  Incorporation of genetic analyses may shed light on 
clinically actionable mutations or epigenetic changes, with the potential of developing 
effective tools for predicting clinical outcomes or advancing personalized cancer treatments. 
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Progressing forward with research and management of patients with urothelial 
carcinoma, it may be beneficial to use variant versus NV+SQD histology as an initial schema 
when considering patients with variant histology.  Willis et al offer a similar suggestion, 
recommending that patients with sarcomatoid, plasmacytoid, and micropapillary variant be 
considered for early cystectomy in the setting of non-invasive disease while the remaining 
variants be treated similarly to non-variant UC until further prognostic and management 
information is available.[3]  Although we are not differentiating within the non-SQD variant, our 
findings certainly support Willis’ recommendations. 
Despite the fact that we are reporting a series of over 400 muscle invasive cystectomies, 
this study is limited by the rarity of variant histology UC and potential single institution biases in 
the identification of variant histology. As this is a retrospective study, there is potential 
uncontrolled confounding between groups. We chose to only include patients identified with 
muscle invasive disease on TURBT to avoid a selection bias, as most variant histology patients 
present at a more advanced clinical stage. This potentially excluded cases that are known to be 
frequently understaged in non-muscle invasive disease.    There is an inherent selection bias 
present in the study as patients managed with neoadjuvant chemotherapy were included in the 
cohort studied. To address this we performed sub-analyses when excluding patients who 
received 1. neoadjuvant chemotherapy, 2. adjuvant chemotherapy, and 3. any systemic 
chemotherapy. We found that there was no difference in the results of the cox regression odel 
ini each of these settings. Nevertheless, this represents one of the largest survival comparisons 
of variant with non-variant histology UC, and we believe it improves knowledge surrounding the 
prognosis for patients with non-SQD variant histology.  
In summary, when comparing non-SQD variant histology to NV+SQD histology, we 
found that even after controlling for systemic chemotherapy and pathologic stage at cystectomy, 
non-SQD variant histology on cystectomy is associated with significantly increased adjusted risk 
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of mortality. While established neoadjuvant chemotherapy regimens followed by radical 
cystectomy for muscle invasive disease should remain the mainstay of treatment in patients with 
non-variant histology and SQD, trials with new neoadjuvant regimens or personalized treatment 
algorithms based on molecular markers should be tailored toward those patients with non-SQD 
variant histology. 
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Figure 1 Kaplan-Meier curve of overall survival (Figure 1a) and disease specific survival (Figure 
1b) comparing Non-SQD variant histology with NV+SQD 
Abbreviations: NV, non-variant; SQD, squamous differentiation variant 
Caption: Worse overall (A) and disease specific (B) survival was noted for non-SQD variant 
histology (p=0.007 each).  
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Table 1 Demographic characteristics of patients with primary urothelial bladder cancer 
undergoing radical cystectomy 
Characteristics NV+SQD Non-SQD variant a p-value b 
n 334 77 
Age, Mean (SD) 67.1 (11) 67.9 (10) 0.558 
Gender (female) 73 (22) 20 (26) 0.436 
Race (Caucasian) 318 (95) 71 (92) 0.291 
Neoadjuvant Chemotherapy 67 (20) 15 (19) 0.909 
Adjuvant Chemotherapy 37 (11) 22 (29) <0.001 
Abbreviations: NV, non-variant; SQD, squamous differentiation; SD, standard deviation 
a Non-SQD variant comprises micropapillary, plasmacytoid, sarcomatoid, glandular 
differentiation, nested, lymphoepithelioma-like, and microcystic variants 
b p-values refer to Pearson’s chi-squared test for categorical variables and Student’s t-test  for 
continuous variables 
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Table 2 Pathologic and survival characteristics of patients with primary urothelial bladder 
cancer  
Characteristics NV+SQD Non-SQD variant a p-value b 
n 334 77 
pT3 or pT4 151 (45) 51 (66) 0.001 
LN+ 83 (25) 37 (48) <0.001 
Surgical margin 14 (4) 10 (13) 0.003 
Overall survival, Median (IQR) NR (30-NR) 28 (12-NR) 0.007 
Abbreviations: NV, non-variant; SQD, squamous differentiation; LN+, lymph node involvement; 
IQR, interquartile range; NR, not reached 
a Non-SQD variant comprises micropapillary, plasmacytoid, sarcomatoid, glandular 
differentiation, nested, lymphoepithelioma-like, and microcystic variants 
b p-values refer to Pearson’s chi-squared test and the Mann-Whitney test 
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Table 3 Cox Proportional Hazards Regression model of characteristics associated with 
overall and disease specific mortality  
Characteristic Overall Mortality Disease Specific Mortality 
Hazard 
Ratio 
95% CI p-value Hazard 
Ratio 
95% CI p-value 
Age 1.01 0.99-1.02 0.347 1.01 0.99-1.03 0.204 
Sex 1.06 0.72-1.57 0.772 1.02 0.63-1.65 0.946 
≥pT3, LN+, +SM a 3.98 2.63-6.03 <0.001 6.75 3.66-12.42 <0.001 
Chemotherapy b 0.59 0.39-0.89 0.012 0.65 0.40-1.06 0.084 
Non-SQD Variant 1.57 1.05-2.35 0.027 1.69 1.05-2.72 0.030 
Abbreviations: LN+, lymph node positive; +SM, positive surgical margins
a in comparison to patients ≤pT2N0 
b Chemotherapy includes any pre-operative or post-operative chemotherapy given 
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